Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models

English version České info

Background:
Sex-specific differences regarding the transmissibility and the course of infection are the rule rather than the exception in the epidemiology of sexually transmitted infections (STIs). Human papillomavirus (HPV) provides an example: disease outcomes differ between men and women, as does the potential for transmission to the opposite sex. HPV vaccination of preadolescent girls was recently introduced in many countries, and inclusion of boys in the vaccination programs is being discussed. Here, we address the question of whether vaccinating females only, males only, or both sexes is the most effective strategy to reduce the population prevalence of an STI like HPV.

Methods and Findings:
We use a range of two-sex transmission models with varying detail to identify general criteria for allocating a prophylactic vaccine between both sexes. The most effective reduction in the population prevalence of infection is always achieved by single-sex vaccination; vaccinating the sex with the highest prevaccine prevalence is the preferred strategy in most circumstances. Exceptions arise only when the higher prevaccine prevalence is due to a substantially lower rate of natural immunity, or when natural immunity is lifelong, and a prolonged duration of infectiousness coincides with increased transmissibility. Predictions from simple models were confirmed in simulations based on an elaborate HPV transmission model. Our analysis suggests that relatively inefficient genital transmission from males to females might render male vaccination more effective in reducing overall infection levels. However, most existing HPV vaccination programs have achieved sufficient coverage to continue with female-only vaccination.

Conclusions:
Increasing vaccine uptake among preadolescent girls is more effective in reducing HPV infection than including boys in existing vaccination programs. As a rule, directing prophylactic immunization at the sex with the highest prevaccine prevalence results in the largest reduction of the population prevalence.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Sex-Specific Immunization for Sexually Transmitted Infections Such as Human Papillomavirus: Insights from Mathematical Models. PLoS Med 8(12): e32767. doi:10.1371/journal.pmed.1001147
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001147

Souhrn

Zdroje

1. HethcoteHWYorkeJA 1984 Gonorrhea: transmission dynamics and control. Lecture notes in biomathematics 56 Berlin Springer-Verlag Available: http://www.math.uiowa.edu/ftp/hethcote/lnb56.pdf. Accessed 12 August 2011 105

2. KretzschmarMvan DuynhovenYTSeverijnenAJ 1996 Modeling prevention strategies for gonorrhea and chlamydia using stochastic network simulations. Am J Epidemiol 144 306 317

3. GrayRTBeagleyKWTimmsPWilsonDP 2009 Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis 199 1680 1688

4. WilliamsBGLloyd-SmithJOGouwsEHankinsCGetzWM 2006 The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med 3 e262 doi:10.1371/journal.pmed.0030262

5. WilsonDPCoplanPMWainbergMABlowerSM 2008 The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A 105 9835 9840

6. CoxAPFossAMShaferLANsubugaRNVickermanP 2011 Attaining realistic and substantial reductions in HIV incidence: model projections of combining microbicide and male circumcision interventions in rural Uganda. Sex Transm Infect E-pub ahead of print. doi:10.1136/sti.2010.046227

7. LiNFranceschiSHowell-JonesRSnijdersPJCliffordGM 2011 Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 128 927 935

8. De VuystHCliffordGMNascimentoMCMadeleineMMFranceschiS 2009 Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 124 1626 1636

9. Miralles-GuriCBruniLCubillaALCastellsaguéXBoschFX 2009 Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 62 870 878

10. ParkinDMBrayF 2006 Chapter 2: the burden of HPV-related cancers. Vaccine 24 Suppl 3 S11 S25

11. AultKA Future II Study Group 2007 Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 1861 1868

12. PaavonenJNaudPSalmerónJWheelerCMChowSN 2009 Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 301 314

13. PalefskyJM 2010 Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 46 Suppl 4 S12 S19

14. DonovanBFranklinNGuyRGrulichAEReganDG 2011 Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 11 39 44

15. von KroghGLaceyCJGrossGBarrassoRSchneiderA 2007 European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogential warts. Sex Transm Infect 76 162 168

16. Advisory Committee on Immunization Practices 2009 Summary report. June 24–26, 2009. Atlanta, Georgia Atlanta (Georgia) Centers for Disease Control and Prevention Available: http://www.cdc.gov/vaccines/recs/acip/downloads/min-archive/min-jun09.pdf. Accessed 21 November 2011

17. SmithMALewJBWalkerRJBrothertonJMNicksonC 2011 The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 29 9112 9122

18. KimJJGoldieSJ 2009 Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339 b3884

19. ElbashaEHDasbachEJ 2010 Impact of vaccinating boys and men against HPV in the United States. Vaccine 28 6858 6867

20. JitMChoiYHEdmundsWJ 2008 Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337 a769

21. BrissonMvan de VeldeNFrancoELDroletMBoilyMC 2011 Incremental impact of adding boys to current human papillomavirus vaccination programs: the role of herd immunity. J Infect Dis 204 372 376

22. Centers for Disease Control and Prevention 2010 National, state, and local area vaccination coverage among adolescents aged 13–17 years—United States, 2009. MMWR Morb Mortal Wkly Rep 59 1018 1023

23. KreimerARRodriguezACHildesheimAHerreroRPorrasC 2010 Proof-of-principle: efficacy of fewer than 3-doses of a bivalent HPV 16/18 vaccine against incident persistent HPV infection in Guanacaste, Costa Rica [abstract]. 26th International Papillomavirus Conference; 3–8 July 2010; Montreal, Canada. Available: http://www.hpv2010.org/main/index.php?option=com_conference&view=presentation&id=1754&conference=1&Itemid=103. Accessed 14 November 2011

24. van LierEAOomenPJGiesbersHDrijfhoutIHde HooghPA 2011 Vaccinatiegraad rijksvaccinatieprogramma Nederland Bilthoven Rijksinstituut voor Volksgezondheid en Milieu Available: http://www.rivm.nl/bibliotheek/rapporten/210021014.pdf. Accessed 21 November 2011

25. AndersonRMMayRM 1991 Infectious diseases of humans: dynamics and control Oxford Oxford University Press 757

26. BogaardsJAXiridouMCoupéVMMeijerCJWallingaJ 2010 Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 171 817 825

27. BogaardsJACoupéVMXiridouMMeijerCJWallingaJ 2011 Long-term impact of HPV vaccination on infection rates, cervical abnormalities and cancer incidence. Epidemiology 22 505 515

28. HandcockMSJonesJH 2006 Interval estimates for epidemic thresholds in two-sex network models. Theor Popul Biol 70 125 134

29. GarnettGPKimJJFrenchKGoldieSJ 2006 Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl 3 S178 S186

30. GiulianoARLeeJHFulpWVillaLLLazcanoE 2011 Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 377 932 940

31. BerkhofJBulkmansNWBleekerMCBulkSSnijdersPJ 2006 Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly diskaryotic smear. Cancer Epidemiol Biomarkers Prev 15 1268 1273

32. BulkmansNWBerkhofJRozendaalLvan KemenadeFJBoekeAJ 2007 Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 1764 1772

33. CoupéVMBerkhofJBulkmansNWSnijdersPJMeijerCJ 2008 Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 98 646 651

34. DiekmannOHeesterbeekJA 2000 Mathematical epidemiology of infectious diseases: model building, analysis and interpretation. Wiley Series in mathematical and computational biology Chichester (United Kingdom) Wiley & Sons 303

35. ElbashaEH 2008 Global stability of equilibria in a two-sex HPV vaccination model. Bull Math Biol 70 894 909

36. BrownVWhiteKA 2010 The HPV vaccination strategy: could male vaccination have a significant impact? Comput Math Methods Med 11 223 227

37. WallingaJvan BovenMLipsitchM 2010 Optimizing infectious disease interventions during an emerging epidemic. Proc Natl Acad Sci U S A 107 923 928

38. AllenJDCoronadoGDWilliamsRSGlennBEscofferyC 2010 A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptance. Vaccine 28 4027 4037

39. CastlePEScarinciI 2009 Should HPV vaccine be given to men? BMJ 339 b4127

40. HullSCCaplanAL 2009 The case for vaccinating boys against human papillomavirus. Public Health Genomics 12 362 367

41. FranceschiSDennyLIrwinKLJeronimoJLopalcoPL 2011 EUROGIN 2010 roadmap on cervical cancer prevention. Int J Cancer 128 2765 2774

42. DorleansFGiambiCDematteLCotterSStefanoffP 2010 The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 15: pii 19730

43. WilliamsJRNokesDJMedleyGFAndersonRM 1996 The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 116 71 89

44. KretzschmarMde WitGASmitsLJvan de LaarMJ 2002 Vaccination against hepatitis B in low endemic countries. Epidemiol Infect 128 229 244

45. Chin-HongPVVittinghoffECranstonRDBrowneLBuchbinderS 2005 Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 97 896 905

46. KimJJ 2010 Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 10 845 852

47. HernandezBYWilkensLRThompsonPJShvetsovYBGoodmanMT 2010 Acceptability of human papillomavirus vaccination among adult men. Hum Vaccin 6 467 475

48. DunneEFNielsonCMStoneKMMarkowitzLEGiulianoAR 2006 Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 194 1044 1057

49. CarterJJKoutskyLAWipfGCChristensenNDLeeSK 1996 The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 927 936

50. HernandezBYWilkensLRZhuXMcDuffieKThompsonP 2008 Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 14 888 894

51. VeldhuijzenNJSnijdersPJReissPMeijerCJvan de WijgertJH 2010 Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 10 862 874

52. GoldieSJO'SheaMCamposNGDiazMSweetS 2008 Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26 4080 4093

53. TracyLGaffHDBurgessCSowSGravittPE 2011 Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali. Clin Infect Dis 52 641 645

54. ChenFH 2006 The impact of microbicides and changes in condom usage on HIV prevalence in men and women. AIDS 20 1551 1553

55. GrayRHLiXKigoziGSerwaddaDNalugodaF 2007 The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 21 845 850